CLAIMS

1. Use of a composition comprising levosimendan, or pharmaceutically acceptable salt(s) or sustained release formulation(s) thereof in the manufacture of a medicament for treating Alzheimer's disease or a related disorder selected from senile dementia of AD type, Parkinson's disease, Lewy body dementia, vascular dementia, mild cognitive impairment, age-associated memory impairment and problem associated with ageing, post-encephalitic parkinsonism, amyotrophic lateral sclerosis, multiple sclerosis or Down syndrome.

2. The use of claim 1, wherein said medicament comprises at least one additional compound selected from aminocaproic acid, acamprosate, amlodipine, argatroban, baclofen, cilostazol, cinacalcet, clopidogrel, dyphylline, fenoldopam, leflunomide, mepacrine, methimazole, phenformin, prilocaine, rifabutin, sulfisoxazole, tadalafil, terbinafine, cinnarizine, eplerenone, carbenoxolone, sulodexide, carbamazine, ciclopirox, amobarbital, cefotetan, erythrityl tetranitrate, methyclothiazide, risedronate, enprofylline, oxtriphylline, paramethadione, cefmenoxime, aprindine, etomidate, mitiglinide, benidipine, and zonisamide, or pharmaceutically acceptable salt(s) or sustained release formulation(s) thereof, for combined, separate or sequential administration.

3. The use of claim 2, wherein said additional compound is selected from aminocaproic acid, baclofen, sulfisoxazole and terbinafine, or pharmaceutically acceptable salt(s) or sustained release formulation(s) thereof.

4. The use of claim 2, wherein said additional compound is selected from acamprosate, amlodipine, argatroban, baclofen, cilostazol, cinacalcet, clopidogrel, dyphylline, fenoldopam, leflunomide, mepacrine, methimazole, phenformin, prilocaine, rifabutin, sulfisoxazole, tadalafil, terbinafine and zonisamide, or pharmaceutically acceptable salt(s) or sustained release formulation(s) thereof.